At present, drugs developed for the above pathogenesis of AD are not well applied in the clinical, such as soluble Aβ protein specific binding agent Solanezumab [3], targeted inhibition of tau protein RO7105705 and LY3303560 [4], and cholinesterase inhibitors galantamine [5], etc. Therefore, the development of novel and effective natural drugs to prevent and improve AD pathology is in particular indispensable. The gene discussed is MAPT; the disease is Alzheimer disease.